StreetInsider.com News Articles

Form 4 IRADIMED CORP For: Jun 01 Filed by: Susi Roger E.

Tue, 02 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260602/26590738.html

Form 4 IRADIMED CORP For: Jun 01 Filed by: Susi Roger E.

Tue, 02 Jun 2026 14:26:00 -0400

si-local-file:///var/storage/secattach/20260602/26590738.html

Form 4 IRADIMED CORP For: May 26 Filed by: Susi Roger E.

Thu, 28 May 2026 15:08:00 -0400

si-local-file:///var/storage/secattach/20260528/26565860.html

Form 4 IRADIMED CORP For: May 26 Filed by: Susi Roger E.

Thu, 28 May 2026 15:08:00 -0400

si-local-file:///var/storage/secattach/20260528/26565860.html

Form 4 IRADIMED CORP For: May 18 Filed by: Susi Roger E.

Wed, 20 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260520/26529067.html

Form 4 IRADIMED CORP For: May 18 Filed by: Susi Roger E.

Wed, 20 May 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260520/26529067.html

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 08:30:00 -0400

ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida.

Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 08:30:00 -0400

Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 08:30:00 -0400

Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 08:30:00 -0400

Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance

Form SCHEDULE 13G/A IRADIMED CORP Filed by: Susi Roger E.

Thu, 14 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260514/26496669.html

Form SCHEDULE 13G/A IRADIMED CORP Filed by: Susi Roger E.

Thu, 14 May 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260514/26496669.html

Form 4 IRADIMED CORP For: May 11 Filed by: Susi Roger E.

Wed, 13 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26486740.html

Form 4 IRADIMED CORP For: May 11 Filed by: Susi Roger E.

Wed, 13 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26486740.html

Form 4 IRADIMED CORP For: May 04 Filed by: Susi Roger E.

Wed, 06 May 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20260506/26442528.html

Form 4 IRADIMED CORP For: May 04 Filed by: Susi Roger E.

Wed, 06 May 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20260506/26442528.html

Form 10-Q IRADIMED CORP For: Mar 31

Fri, 01 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260501/26417691.html

Form 10-Q IRADIMED CORP For: Mar 31

Fri, 01 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260501/26417691.html

Form 8-K IRADIMED CORP For: May 01

Fri, 01 May 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260501/26412881.html

Form 8-K IRADIMED CORP For: May 01

Fri, 01 May 2026 09:16:00 -0400

si-local-file:///var/storage/secattach/20260501/26412881.html

Iradimed Corp. (IRMD) Tops Q1 EPS by 3c ; Offers Guidance

Fri, 01 May 2026 09:07:52 -0400

Iradimed Corp. (NASDAQ: IRMD) reported Q1 EPS of $0.49, $0.03 better than the analyst estimate of $0.46. Revenue for the quarter came in at $22 million versus the consensus estimate of $20.8 million.

GUIDANCE:

Iradimed Corp. sees Q2 2026 EPS of $0.44-$0.48, versus the consensus of $0.47. Iradimed Corp. sees Q2 2026 revenue of $20-21 million, versus the consensus of $21.13 million.

Iradimed Corp. sees FY2026 EPS of $2.06-$2.21, versus the consensus of $2.08. Iradimed Corp. sees FY2026 revenue of $91-96 million, versus the consensus of $102.8 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

Iradimed Corp. (IRMD) Tops Q1 EPS by 3c ; Offers Guidance

Fri, 01 May 2026 09:07:52 -0400

Iradimed Corp. (NASDAQ: IRMD) reported Q1 EPS of $0.49, $0.03 better than the analyst estimate of $0.46. Revenue for the quarter came in at $22 million versus the consensus estimate of $20.8 million.

GUIDANCE:

Iradimed Corp. sees Q2 2026 EPS of $0.44-$0.48, versus the consensus of $0.47. Iradimed Corp. sees Q2 2026 revenue of $20-21 million, versus the consensus of $21.13 million.

Iradimed Corp. sees FY2026 EPS of $2.06-$2.21, versus the consensus of $2.08. Iradimed Corp. sees FY2026 revenue of $91-96 million, versus the consensus of $102.8 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

Fri, 01 May 2026 08:30:00 -0400

Announces Regular Quarterly Cash Dividend of $0.20 Per Share

Reaffirms Full-Year 2026 Revenue and Earnings Guidance

Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.
Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.
Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter

IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

Fri, 01 May 2026 08:30:00 -0400

Announces Regular Quarterly Cash Dividend of $0.20 Per Share

Reaffirms Full-Year 2026 Revenue and Earnings Guidance

Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.
Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.
Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter

IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

Fri, 01 May 2026 08:30:00 -0400

Announces Regular Quarterly Cash Dividend of $0.20 Per Share

Reaffirms Full-Year 2026 Revenue and Earnings Guidance

Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.
Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.
Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter